key: cord-0949813-y75hnumb authors: Kempf, W.; Kettelhack, N.; Kind, F.; Courvoisier, S.; Galambos, J.; Pfaltz, K. title: ‘COVID arm’ – histological features of a delayed‐type hypersensitivity reaction to Moderna mRNA‐1273 SARS‐CoV2 vaccine date: 2021-07-24 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17506 sha: 0c9281711192e8fbc64074fcee1e0e0b8c61fa63 doc_id: 949813 cord_uid: y75hnumb To prevent SARS-CoV2 infection, mRNA vaccines have been developed including the mRNA-1273 (Moderna), a lipid-nanoparticle-encapsulated mRNA vaccine (1). In some individuals a cutaneous localized reaction with erythema and swelling on the upper arm at the injection site occurs which is referred as "COVID arm" (2, 3). It is considered as delayed type hypersensitivity reaction (DTHR) and occurs mostly in individuals after vaccination with the Moderna vaccine, but rarely with other mRNA vaccines (2, 3). Dear Editor, To prevent SARS-CoV2 infection, mRNA vaccines have been developed including the mRNA-1273 (Moderna, Inc., Cambridge, MA, USA), a lipid nanoparticle-encapsulated mRNA vaccine. 1 In some individuals, a cutaneous localized reaction with erythema and swelling on the upper arm at the injection site occurs which is referred as 'COVID arm'. 2, 3 It is considered as delayed-type hypersensitivity reaction (DTHR) and occurs mostly in individuals after vaccination with the Moderna vaccine, but rarely with other mRNA vaccines. 2, 3 Whereas the clinical presentation is well characterized, the data on the histological features of this reaction are very sparse. The clinicopathological features of the patients and biopsies are summarized in Table 1 . In all three patients, an erythema occurred on the left upper arm 6-7 days after the first injection of the Moderna (mRNA-1273 SARS-CoV2) vaccine. Skin biopsies were performed from the centre of the erythema in two patients and from the periphery in one patient. Histology revealed subtle and only very focal epidermal changes with spongiosis and exocytosis of a few lymphocytes in all biopsies. There was a perivascular and occasionally sleeve-like inflammatory infiltrate in the upper and mid dermis which was predominantly composed of small lymphocytes with an admixture of a variable number of eosinophilic granulocytes (Figs 1a and 2a,b). Immunophenotyping revealed that the lymphocytic component consisted almost exclusively of CD3-positive T cells with an admixture of only very few CD20-positive B cells. CD4-positive T cells accounted for 60-90% of all T cells and CD8-positive T cells for the remaining 10-40% (Fig. 1b,c) . FOXP3-positive regulatory T-helper cells (Tregs) accounted for 5-10% of the lymphocytes. In addition, few CD56-positive T/NK cells, scattered CD138-positive plasma cells and CD123-positive plasmacytoid dendritic cells (PDCs) were present. The histological findings in our series are compatible with erythema annulare centrifugum (EAC) and are similar to the findings of previously reported six skin biopsies. 2, 4, 5 Our data expand the immunophenotypic profile as they document the presence of few B cells including plasma cells, PDCs and Tregs. Post-vaccine EAC is an immunological reaction pattern which can be interpreted as a DHRT. It is distinct from the urticarial aspect of an acute-type allergic reaction (urticaria) and from contact allergic spongiotic dermatitis as classic localized DTHR. The predominance of CD4 + T cells can be explained by the strong response of CD4-positive type 1 helper T cells elicited by the vaccine. 6 As in other hypersensitivity reactions, eosinophils are present at variable number. Post-vaccine EAC represents the histomorphological correlate for a localized DTHR known as COVID arm due mRNA vaccines. Remarkably, this immunological reaction pattern was also observed as a complication of COVID-19. 7 The pathogenesis of EAC has not yet been elucidated in detail. Various triggers have been identified such as food components and drugs including immunotherapy. 8 Lymphocytes from patients with EAC showed an increased release of IFN-c. 9 The COVID-19 mRNA vaccine BNT162b1 induces Thelper type 1-skewed T-cell immune responses with expansion of CD4 + and CD8 + T cells which are specific to the receptorbinding domain of the SARS-CoV-2 spike protein and produce interferon-c. 10 These findings support the concept of EAC as a T-cell-mediated DTHR in which IFN-c is a crucial pathogenetic factor. It is still unclear which component of the Moderna vaccine is responsible for the induction of post-vaccine EAC. The mRNA encoding the spike protein itself seems not to be the primary culprit as also other mRNA vaccines very rarely induce the same reaction. In conclusion, the histomorphological correlate of the localized cutaneous DTHR to mRNA vaccines against SARS-CoV-2 corresponds to EAC as an immunological reaction pattern. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Delayed localized hypersensitivity reactions to the moderna COVID-19 vaccine Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases Delayed large local reactions to mRNA vaccines Delayed large local reactions to mRNA vaccines. Reply Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults Erythema annulare centrifugum with anosmia and ageusia in a SARS-CoV-2 exposed patient successfully treated with doxycycline Erythema annulare centrifugum: a review of 24 cases with special reference to its association with underlying disease Autoimmune progesterone dermatitis manifested as erythema annulare centrifugum: confirmation of progesterone sensitivity by in vitro interferon-gamma release COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses The patients in this manuscript have given written informed consent to publication of their case details. None to declare.